Author: Biembengut, Ãsis Venturi; de Souza, Tatiana de Arruda Campos Brasil
Title: Coagulation modifiers targeting SARS-CoV-2 main protease Mpro for COVID-19 treatment: an in silico approach Cord-id: vcscrqyp Document date: 2020_6_1
ID: vcscrqyp
Snippet: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection depends on viral polyprotein processing, catalysed by the main proteinase (Mpro). The solution of the SARS-CoV-2 Mpro structure allowed the investigation of potential inhibitors. This work aims to provide first evidences of the applicability of commercially approved drugs to treat coronavirus disease-19 (COVID-19). We screened 4,334 compounds to found potential inhibitors of SARS-CoV-2 replication using an in silico approach.
Document: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection depends on viral polyprotein processing, catalysed by the main proteinase (Mpro). The solution of the SARS-CoV-2 Mpro structure allowed the investigation of potential inhibitors. This work aims to provide first evidences of the applicability of commercially approved drugs to treat coronavirus disease-19 (COVID-19). We screened 4,334 compounds to found potential inhibitors of SARS-CoV-2 replication using an in silico approach. Our results evidenced the potential use of coagulation modifiers in COVID-19 treatment due to the structural similarity of SARS-CoV-2 Mpro and human coagulation factors thrombin and Factor Xa. Further in vitro and in vivo analysis are needed to corroborate these results.
Search related documents:
Co phrase search for related documents- ace inhibitor and acute cardiac injury: 1, 2
- ace inhibitor and acute phase: 1
- ace receptor and active site: 1, 2, 3, 4
- ace receptor and acute cardiac injury: 1, 2, 3, 4, 5
- ace receptor and acute phase: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date